| Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | |
|---|---|---|---|---|---|
Research and development expenses, net | |||||
6,837 | 5,491 | 5,837 | 2,832 | 2,893 | |
General and administrative expenses | |||||
3,164 | 3,571 | 6,626 | 1,703 | 1,090 | |
Other income | |||||
- | - | - | - | 11 | |
Operating loss | |||||
-10,001 | -9,062 | -12,463 | -4,535 | -3,972 | |
Finance income (expenses), net | |||||
236 | 244 | 173 | 3,925 | 604 | |
Loss before tax | |||||
-9,765 | -8,818 | -12,290 | -610 | - | |
Taxes on income | |||||
6 | 8 | 0 | 0 | - | |
Net loss for the period | |||||
-9,771 | -8,826 | -12,290 | -610 | -3,368 | |
Net loss per ordinary share basic and diluted | |||||
6.72 | 7.31 | 12.67 | 1.18 | 3.27 | |
Weighted average number of ordinary shares outstanding - basic and diluted (in thousands) | |||||
1,455 | 1,208 | 993 | 2,181 | 1 | |